1,3-Bis(5-hydroxypentanoylamino)propan-2-yl dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: 1,3-Bis(5-hydroxypentanoylamino)propan-2-yl dihydrogen phosphate
• 英文别名: 1,3-bis(5-hydroxypentanoylamino)propan-2-yl dihydrogen phosphate
• 化学式: C₁₃H₂₇N₂O₈P
• 分子量: 370.34
• InChiKey: NSCKHVOITOHJLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  165
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• PROTEIN BIOSENSORS, CROSS REACTIVE SENSOR ARRAYS AND METHODS OF USE THEREOF
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：US20150362490A1

  公开（公告）日：2015-12-17

  The present invention is directed to fluorescent protein biosensors based on oligonucleotide cross reactive sensor arrays including a selective and a non-selective protein surface binding domain for protein detection. Interaction of different protein isoforms with the sensors of this invention yields a unique optical signature for each protein. The unique optical signature allows differentiating between closely related protein isoforms and diagnosing diseases and disorders associated with the proteins also in biofluids.

  本发明涉及基于寡核苷酸交叉反应传感器阵列的荧光蛋白生物传感器，其中包括选择性和非选择性蛋白质表面结合域用于蛋白质检测。不同蛋白质亚型与本发明的传感器的相互作用产生每种蛋白质的独特光学特征。独特的光学特征允许区分密切相关的蛋白质亚型，并在生物流体中诊断与蛋白质相关的疾病和障碍。
• Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
  申请人：Translate Bio MA, Inc.

  公开号：US10844375B2

  公开（公告）日：2020-11-24

  The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.

  本公开提供了多聚物寡核苷酸化合物，包括两个或多个靶向特异性寡核苷酸（如反义寡核苷酸（ASO）），每个寡核苷酸都具有抗裂解性，并通过可裂解连接体连接在一起。特别是两个或更多链接的靶标特异性寡核苷酸，每个都针对不同的靶标，可以同时抑制多个基因的表达水平，同时表现出良好的药代动力学和药效学特性。还提供了所述化合物的制造方法和用途。
• MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
  申请人：RANA THERAPEUTICS, INC.

  公开号：US20150247141A1

  公开（公告）日：2015-09-03

  The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided
• MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS HAVING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS
  申请人：RaNA Therapeutics, Inc.

  公开号：US20150315585A1

  公开（公告）日：2015-11-05

  The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided
• METHODS OF DELIVERING MULTIPLE TARGETING OLIGONUCLEOTIDES TO A CELL USING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS
  申请人：RaNA Therapeutics, Inc.

  公开号：US20150315586A1

  公开（公告）日：2015-11-05

  The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided